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Abstract ApoC-III was discovered almost 50 years ago, but
for many years, it did not attract much attention. However, as
epidemiological and Mendelian randomization studies have
associated apoC-III with low levels of triglycerides and de-
creased incidence of cardiovascular disease (CVD), it has
emerged as a novel and potentially powerful therapeutic ap-
proach to managing dyslipidemia and CVD risk. The
atherogenicity of apoC-III has been attributed to both direct
lipoprotein lipase-mediated mechanisms and indirect mecha-
nisms, such as promoting secretion of triglyceride-rich lipo-
proteins (TRLs), provoking proinflammatory responses in
vascular cells and impairing LPL-independent hepatic clear-
ance of TRL remnants. Encouraging results from clinical trials
using antisense oligonucleotide, which selectively inhibits
apoC-III, indicate that modulating apoC-III may be a potent
therapeutic approach to managing dyslipidemia and cardio-
vascular disease risk.
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Introduction
Apolipoprotein C-III (apoC-III) was first identified by Brown
et al. in 1969 as a regulator of triglyceride-rich lipoproteins
(TRLs) in the circulation [1]. In the blood, it is mainly present
in TRLs (chylomicrons and VLDL) and, to a lesser extent, in
LDL and HDL particles. Shortly after its discovery, it was
identified as an inhibitor of lipoprotein lipase (LPL) activity
and a key regulator of TRL concentrations in plasma [2, 3]. In
addition to its potent inhibitory capacity on LPL-mediated
lipolysis, apoC-III has also been shown to facilitate hepatic
VLDL assembly and secretion. ApoC-III is not only a critical
modulator of TRLs but also contributes to the atherogenicity
of low- and high-density lipoprotein (LDL and HDL) particles
[4–7]. Substantial evidence has emerged to indicate that apoC-
III has several additional functions, including modulation of
endothelial function and inflammation [8, 9].
The connection of apoC-III with hypertriglyceridemia and
CVD risk has been confirmed in extensive animal and humans
studies [10, 11]. Furthermore, given that TRL remnants are
now recognized as a causal risk factor for CVD and that loss-
of-function mutations of apoC-III are characterized by a ro-
bust lowering of serum triglycerides and reduced CVD risk
[12, 13•, 14••, 15], apoC-III has been identified as an attractive
target for the prevention of CVD. This review evaluates the
role of apoC-III in the pathogenesis of CVD and summarizes
its role as a novel therapeutic target.
Regulation of Apoc-III
ApoC-III is the most abundant C-apolipoprotein in humans. It
is found not only in triglyceride-rich chylomicrons and very
low-density lipoproteins (VLDLs) but also in HDL. In
humans, apoC-III is mainly expressed in hepatocytes and
enterocytes. Its expression is chiefly regulated at the
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transcriptional level, and the regulatory sequences of the
APOC3 gene have been extensively described (reviewed in
[16]). The APOC3 gene contains two regulatory elements that
act as a common enhancer for a gene cluster on 11q23 that
regulates the expression of three apolipoprotein genes:
APOC3, APOA1, and APOA4 [16, 17].
Promoter analysis of the APOC3 gene has identified bind-
ing sites for several transcription factors including the carbo-
hydrate response element binding protein (ChREBP) [18–20].
Thus, glucose and plasma triglyceride metabolism are linked
via the regulation of APOC3 expression. Additional transcrip-
tion factors that bind to the APOC3 gene include the nuclear
receptors hepatocyte nuclear factor-4α (HNF-4α) [21] and
liver X receptors (LXRs) [22]. Interestingly, the expression
of APOC3 is upregulated by glucose and downregulated by
insulin. This contrasts with most other genes in the glycolytic
and lipogenic pathways, which are regulated positively both
by glucose and insulin [23]. It has, therefore, been proposed
that the glucose-mediated expression of APOC3may contrib-
ute to lower lipolysis and consequently to an increase in pe-
ripheral glucose handling [20]. Substantial evidence indicates
that dysregulation of the insulin signaling pathway via FoxO1
aggravates APOC3 expression as the inhibitory effect of insu-
lin on APOC3 expression that is lost [24]. This mechanism
may explain why apoC-III concentrations are increased in
insulin-resistant states such as obesity, the metabolic syn-
drome, type 2 diabetes, and hypertriglyceridemia [10, 11, 25].
ApoC-III is a small protein (79 amino acid residues) that
contains two amphipathic helices [26]. We still lack a detailed
structure-function understanding of apoC-III, and it is not
clear which regions are most important for attachment to lipids
[26–29]. ApoC-III can undergo posttranslational modification
on threonine 74, and three different glycoforms have been
described with zero, one, or two sialic acids (termed apoC-
III0, apoC-III1, and apoC-III2) [30]. The degree of sialylation
of apoC-III has been reported to influence its function as
apoC-III2 inhibits LPL-mediated hydrolysis of TRLs less ef-
ficiently than apoC-III1 [31], despite having an apparent two-
fold greater affinity for TRL than the other two apoC-III iso-
forms [32].
Function of Apoc-III
In addition to inhibiting LPL-mediated lipolysis of TRLs,
apoC-III binds surface heparan sulfate proteoglycans
(HSPGs) on the liver and cellular receptors, including the
HDL receptor SR-BI [33]. However, the significance of bind-
ing to SR-BI is still unclear.
Inhibition of LPL-mediated Lipolysis Lipolysis of TRLs is
mediated by LPL, which resides on cellular surfaces. ApoC-
III has been shown in vitro to inhibit lipolysis by several
mechanisms, including displacing lipoproteins from the
negatively charged cell surface [34], inducing conformational
changes in apoE and inhibiting the activation of LPL by
displacing the LPL activator apoC-II from the lipoprotein sur-
face [35]. In addition, studies in vivo with apoC-III transgenic
mice have demonstrated that overexpression of apoC-III in-
duces marked hypertriglyceridemia due to accumulation of
remnant particles with increased apoC-III and decreased
apoE content compared with controls [36].
Inhibition of Lipoprotein Binding to HSPGs and the LDL
Receptor Family ApoC-III displaces apoE from lipoprotein
particles [37]. This displacement can either be complete or
involve only the N-terminal domain of apoE [37]. Since
apoC-III impairs the clearance of TRLs and their remnants,
whereas apoE mediates their clearance (by binding to hepatic
HSPG and the LDL receptor), the relative proportions of
apoC-III and apoE on apoB-containing lipoproteins regulate
the metabolism of these lipoproteins, which is reflected in
LDL and HDL subspecies. This is a very complex area of
research, and Dr Sacks has made significant contributions in
clarifying the crucial roles of apoE and apoC-III in apoB-
lipoprotein metabolism [6].
HumanKinetic StudiesRecent evidence from kinetic studies
showed that dual metabolic defects contribute to elevated
TRLs in the atherogenic dyslipidemia of abdominally obese
men [38•, 39, 40]. In fact, reduced catabolism of TRLs
resulting from increased levels of plasma apoC-III was shown
to be a more important predictor of plasma triglycerides than
increased secretion rate of TRLs driven by liver fat content
[38•]. Indeed, kinetic studies in humans have also provided
direct evidence to show that apoB-containing lipoproteins are
removed significantly more slowly from the circulation if they
contain apoC-III [41]. These results may indicate that apoC-III
concentration may be a good biomarker of the residual risk of
CVD in subjects with atherogenic dyslipidemia; this issue
remains a major clinical problem in statin-treated subjects.
The finding that removal of TRLs from the circulation is a
more important determinant of plasma TG than secretion of
TRL is interesting, but it remains to be clarified whether the
apoC-III-induced impaired clearance of VLDL particles in
subjects with atherogenic dyslipidemia is predominantly due
to reduced lipolytic capacity or to the impaired removal of
TRL remnants by the liver. This question is of importance
when considering the potential of apoC-III inhibition as a
novel treatment modality. Because the lipid oxidation capacity
of the liver is limited, a potential concern is that increased lipid
load from the uptake of remnant particles may lead to excess
fat accumulation in hepatocytes, resulting in non-alcoholic
fatty liver disease [42].
Recently, apoC-III has also been implicated in VLDL se-
cretion [43–45]. Overexpression of apoC-III in mice and
in vitro resulted in increased secretion of triglyceride-rich
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VLDL particles [43]. Structure-function analysis of apoC-III
has identified two domains in apoC-III that seem to influence
the formation and secretion of VLDL [43]. However, inhibi-
tion of apoC-III synthesis by apoC-III antisense oligonucleo-
tides (ASO) did not reduce VLDL secretion in mice [46] so
the significance of apoC-III for VLDL secretion requires fur-
ther study, particularly in humans.
Measurements of ApoC-III Concentrations
Standardized clinical immunoassays for the measurements of
apoC-III concentrations have not been easily available. The
most common system to measure plasma apoC-III
concertation has been the immunoturbidimetric assay provid-
ed by automatic autoanalyzers [47]. More recently, a sensitive
sandwich ELISA to quantify apoC-III concentrations was de-
veloped for commercial use [48]. However, because apoC-III
circulates in multiple glycoforms that are differentially distrib-
uted in lipoprotein fractions (VLDL, LDL, and HDL), the
measurement of plasma apoC-III concentrations is not enough
to understand the complexity of apoC-III in lipoprotein me-
tabolism, particularly in the context of novel apoC-III ASO
therapies. Therefore, it is critical that novel assays with high
sensitivity and specificity be developed. Furthermore, to better
understand the clinical importance of the different glycoforms,
assays that can be easily performed in routine clinical chem-
istry laboratories are needed [5, 30, 49–51].
Role of ApoC-III in Atherogenesis and Inflammation
Recent epidemiological studies have clearly demonstrated that
apoC-III is associated with higher risk of CVD, but what
makes apoC-III atherogenic? As discussed above, apoC-III
regulates lipid metabolism through multiple mechanisms with
adverse effects especially on TRLs and their remnants (Fig. 1).
In addition to effects on lipid metabolism, apoC-III has been
shown to influence atherogenesis by increasing the affinity of
LDL for artery wall proteoglycans, and thus increasing accu-
mulation of atherogenic lipoproteins in the vessel wall [7,
52–56]. The mechanism was elusive since apoC-III by itself
does not bind artery wall proteoglycans. However, Hiukka
et al. identified a potential explanation by demonstrating that
apoC-III influences the lipid composition not only of TRLs
but also of LDL [7]. They investigated subjects with type 2
diabetes and showed that LDL with a high apoC-III/apoB
molar ratio is associated with a reduction in unesterified cho-
lesterol, sphingomyelin, and ceramide, but not phosphatidyl-
choline [7]. These changes in lipid composition associate with
higher membrane fluidity, thus allowing apoB to acquire a
conformation that is more favorable for proteoglycan binding
[7, 57].
Following subendothelial retention in the artery wall, LDL
is exposed to several enzymes, including sphingomyelinases
(SMase), that promote aggregation and fusion of retained li-
poproteins [58]. Interestingly, apoC-III is a SMase activator
and apoC-III-enriched LDL displays increased susceptibility
to hydrolysis and aggregation by SMase [7, 59]. ApoC-III has
also been linked to inflammation as apoC-III alone, or as a
component of TRLs and LDL, induces activation of adhesion
molecules and the proinflammatory nuclear factor-kB in
monocytes and endothelial cells [60, 61].
ApoC-III and CVD Risk
Data from several observational studies show that plasma
apoC-III levels associate with manifestations of CVD and
the progression of coronary artery disease [5, 11].
Epidemiological studies have further demonstrated that
apoC-III in plasma, VLDL, and LDL predicts CVD [10, 11,
62–65]. Importantly, in a 15-year follow-up study, age- and
sex-adjusted apoC-III concentrations were shown to predict
CVD mortality [65]. Recently, Qamar et al. reported that
apoC-III levels in patients with type 2 diabetes patients
(n = 1422) associate with elevation of triglycerides and higher
coronary artery calcification (CAC) score, a measure of sub-
clinical atherosclerosis [66•]. Notably, this relationship be-
tween apoC-III and CAC was found to be triglyceride depen-
dent. The positive association of apoC-III levels with CVD
has recently been confirmed in a meta-analysis of published
data [5]. The finding of an inverse relationship between plas-
ma apoC-III levels and incident CVD reported in a large case–
control study of type 2 diabetic subjects (n = 1123) was unex-
pected [67]. Normally, plasma apoC-III correlates strongly
with triglyceride levels. However, in this cohort of type 2
diabetics, this correlation was, at best, only modest [67].
Overall, the association of apoC-III with CVD risk has been
reported to be independent of statin use, suggesting that apoC-
III could become a marker for the residual risk of CVD in
statin-treated patients with atherogenic dyslipidemia [63,
66•, 68].
In addition, higher apoC-III content in both VLDL and
LDL shows consistent links with CVD events, highlighting
the multifaceted role of apoC-III as a proatherogenic apolipo-
protein (7). The available data on apoC-III in HDL particles
are heterogeneous and less clear. However, two studies report-
ed that apoC-III in HDL particles is associated with increased
CHD risk [63, 69]. Remaining important questions are how
apoC-III modifies HDL to become proatherogenic and if this
may explain the unexpected findings in subjects with type 2
diabetes reported by Looker et al. [67].
The rapid development of molecular genetic technology
has provided the tools to determine whether apoC-III has a
causal role as a proatherogenic protein. Recently, a compre-
hensive meta-analysis of three main apoC-III polymorphisms
(SstI, T-455C, and C-482T) known to associate with hypertri-
glyceridemia in mice [36] reported that two polymorphisms
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(SstI and T-455C) significantly increased the susceptibility to
CHD in humans [70]. The association of the apoC-III T-455C
with increased CVD risk was confirmed in another meta-
analysis [71]. In contrast, some evidence emerged that rare
variants of apoC-III associated with low triglycerides and high
HDL cholesterol [72, 73]. In line with the lipid profile of low
triglycerides and high HDL cholesterol, a lifelong deficiency
of apoC-III has been shown to associate with reduced subclin-
ical atherosclerosis, being cardioprotective [74]. Together,
these data support strongly the link of polymorphisms in
apoC-III with serum levels of triglycerides, as well as with
either promotion or prevention of CVD.
Two large Mendelian randomization studies have recently
shown that polymorphisms in the APOC3 gene were associ-
ated with decreased incidence of CVD [13•, 14••]. In these
cohorts, three loss-of-function mutations in the APOC3 gene
were identified and the heterozygote carriers of these rare
variants had about 39–44 % lower serum triglyceride levels,
about 46 % lower apoC-III levels and a 36–40 % lower risk of
CHD than non-carriers. Furthermore, the reduced risk of CVD
was independent of statin use. Recently, carriers of the three
loss-of-function mutations of APOC3 were shown to exhibit
lower triglyceride levels together with higher HDL cholesterol
and a decreased burden of coronary arterial calcification (de-
creased median CAC score), but no difference was observed
in either carotid plaque or carotid intima-media thickness [68].
Potential Therapies to Reduce ApoC-III Plasma Levels
Currently available tools to reduce apoC-III levels and
consequently TRLs and their remnants remain limited.
Peroxisome proliferator activated receptor (PPAR) alfa
agonists are known to downregulate the expression of
apoC-III and to reduce its plasma levels in both animal
and human studies [75]. Given the fact that apoC-III
levels are increased in people with type 2 diabetes [76]
and that fibrates reduce apoC-III levels [75, 77], it is sur-
prising that so far no data exist on a potential link be-
tween the reduction of apoC-III and CVD outcomes from
randomized clinical trials of fibrates. Statins are reported
to inhibit APOC3 mRNA levels in liver cells [78] and a
small reduction of apoC-III levels by statins has been
reported in several relatively small studies [11, 79, 80].
The strategy to search for naturally occurring loss-of-
function mutations that associate with decreased cardiovascu-
lar disease has proven successful for identifying novel thera-
peutic targets. For example, the translation of findings on
proprotein convertase subtilisin/kexin type 9 (PCSK9) vari-
ants, from their identification in 2003 [81] to the currently
ongoing phase 3 clinical outcome trials of PCSK9 inhibition
with almost 40 000 persons included [82], has been performed
in record time. Keys for this rapid translation from bench to
clinic encompass the development of modern genetics and
new techniques such as silencing RNA and novel human an-
tibody technology [83]. ApoC-III follows the same modern
pipeline for drug discovery, as ISIS Pharmaceuticals has de-
veloped an apoC-III ASO (volanesorsen) that inhibits the bio-
synthesis of apoC-III [46, 84]. ApoC-III ASO has been shown
to robustly reduce both plasma apoC-III and triglyceride
levels in multiple animal models and human volunteers in
phase I studies [46]. Recent data from phase II studies con-
firmed that apoC-III ASO-mediated suppression of apoC-III
leads to marked lowering (up to 90 %) of serum apoC-III and
up to about an 80 % reduction of VLDL triglyceride levels in
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Fig. 1 Proatherogenic action of apoC-III on lipid metabolism and
atherogenicity. ApoC-III exerts strong atherogenic functions through
both indirect and direct mechanisms. These include inducing
oversecretion of apoC-III-containing triglyceride-rich lipoproteins
(TRLs). These lipoproteins accumulate in the circulation by three
mechanisms: (1) impaired lipolysis of large TRLs to smaller remnant
particles, (2) impaired LPL-mediated lipolysis of TRLs on capillaries,
and (3) impaired LPL-independent and LPL-dependent hepatic
clearance of TRL remnants. In addition, apoC-III promotes
proinflammatory responses in endothelial cells and monocytes and
increases the binding affinity of LDL, leading to increased
accumulation of atherogenic lipoproteins in the artery wall
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patients with familial chylomicron syndrome and with vari-
able types of hypertriglyceridemia [46, 85••, 86••]. The data
also demonstrated that the lowering of serum apoC-III levels
and triglycerides by apoC-III ASO was dose-dependent and
selective [46]. In addition, volanesorsen markedly reduced
TRL remnants [85••]. These observations, together with the
reduction of TRLs in the absence of LPL, support the exis-
tence of LPL-independent pathway(s) regulated by apoC-III
for removal of triglycerides [86••]. Safety data from these
short-term studies with apoC-III ASO therapy have not raised
any major concerns; volanesorsen appears to have a good
safety profile and has been well tolerated [85••, 86••]. Phase
III trials with volanesorsen are ongoing (the APPROACH
study and COMPASS) and will clarify the efficacy of the drug
intervention in subjects with severe hypertriglyceridemia de-
fined as triglyceride levels above 5.7 mmol/l (>500 mg/dl)
[87].
Gaps in Knowledge of ApoC-III
Important contributions to our understanding of apoC-III
have been made by several research groups. However,
there are still important gaps in our knowledge of apoC-
III (see Table 1), the closing of which will require addi-
tional research.
Conclusions
Population studies have demonstrated that plasma apoC-
III is strongly associated with CVD risk. For many years,
the atherogenicity of apoC-III was attributed to its LPL-
mediated effects. However, recent evidence reveals that
apoC-III has additional roles, for example in promoting
VLDL formation and assembly and proinflammatory re-
sponses in endothelial cells and monocytes and impairing
LPL-independent hepatic clearance of TRL remnants.
Encouraging results from early clinical trials demonstrate
that modulation of apoC-III per se is a novel and potent
therapeutic approach to managing dyslipidemia and CVD
risk.
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